Clinical Trials

Accrual Status
Limit to SWOG Trials

1052 Results

Open
Phase
Accrual
0%
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S1900N

A Randomized Phase II Study of Sacituzumab Govitecan alone, Ivonescimab alone, or Sacituzumab Govitecan and Ivonescimab in Participants with Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

Status Notes
The above-referenced study will be open to participant accrual, effective 12:00 p.m. Pacific Time on August 3, 2026.
Research Committee(s)
LungMAP
Activated
08-03-2026
ClinicalTrials.gov Registry Number
07393555
Open
Phase
Accrual
0%
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S2505

Phase III Randomized Study Testing Non-Inferiority of Short-Course Ultra-Hypofractionated Radiation (UHRT-5) Versus Standard Fractionation (RT-25) for Stage II-IIIB, Extremity, Resectable Soft Tissue Sarcoma

Status Notes
Effective 7/6/2026 S2505 is active.
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
07-06-2026
ClinicalTrials.gov Registry Number
07615049
Open
Phase
Accrual
1%
SWOG Clinical Trial Number
S2504

A Randomized Phase III Study of PIRtobrutinib plus R-CHOP vs. R-CHOP for Patients with Previously UntreateD RIchter TrAnsforMation (RT) (pirAMID)

Status Notes
Study is active as of 06/01/2026.
Research Committee(s)
Leukemia
Lymphoma
Activated
06-01-2026
ClinicalTrials.gov Registry Number
07220187
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S2424CD

A Randomized Controlled Trial of an Intervention called Algorithm-Enabled Patients Activated in Cancer Care through Teams (A-PACT) to Improve Goals of Care Communication for People with Cancer

Status Notes
Activation 06/01/2026
Research Committee(s)
Cancer Care Delivery
Activated
06-01-2026
ClinicalTrials.gov Registry Number
07278739